Physician profile
Sandhya Menon
NPI 1013160423
$2,323.96
in general payments reported to CMS, 2019-2025
18 companies · $407 in 2025
The $407 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $35.24 · 2021: $363 · 2022: $637 · 2023: $485 · 2024: $397 · 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,288.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $410.09 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $393.49 | 2021-2024 | |
| Novo Nordisk INC | $203.10 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $166.76 | 2023-2025 | Repatha, Otezla, Otezla |
| Exact Sciences Corporation | $163.69 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.95 | 2020-2025 | Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals Lp | $141.30 | 2021-2025 | Farxiga, Airsupra |
| Horizon Therapeutics Plc | $132.17 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $126.52 | 2021-2023 | |
| Glaxosmithkline, LLC. | $103.00 | 2022-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Currax Pharmaceuticals LLC | $86.22 | 2022-2023 | Contrave, Onzetra Xsail |
| Biohaven Pharmaceuticals, INC. | $66.80 | 2021 | |
| Abbott Laboratories | $49.62 | 2022-2025 | Freestyle Libre 3 |
| Pfizer INC. | $40.15 | 2023 | |
| Novartis Pharmaceuticals Corporation | $35.74 | 2022-2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.92 | 2021 | |
| Eisai INC. | $16.97 | 2025 | |
| Esperion Therapeutics, INC. | $15.47 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandhya Menon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.